StockData
Structure Therapeutics Inc. logo

Structure Therapeutics Inc. (GPCR) stock

GPCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$16.13−0.99 (-5.78%)

Close on Nov 20, 2026Market cap $1.15BP/E –Yield –

Structure Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Structure Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$224.50M. For fiscal 2025 it was -$225.81M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$225.81M–
FY2024Dec 31, 2024-$117.93M–
FY2023Dec 31, 2023-$81.66M–
FY2022Dec 31, 2022-$46.28M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$120.07M–
Q1 FY2026Mar 31, 2026$14.05M–
Q4 FY2025Dec 31, 2025-$65.91M–
Q3 FY2025Sep 30, 2025-$52.57M–
Q2 FY2025Jun 30, 2025-$54.79M–
Q1 FY2025Mar 31, 2025-$52.54M–
Q4 FY2024Dec 31, 2024-$36.48M–
Q3 FY2024Sep 30, 2024-$20.38M–
Q2 FY2024Jun 30, 2024-$26.82M–
Q1 FY2024Mar 31, 2024-$34.24M–
Q4 FY2023Dec 31, 2023-$22.89M–
Q3 FY2023Sep 30, 2023-$21.38M–
Q4 FY2022Dec 31, 2022-$12.10M–
Q3 FY2022Sep 30, 2022-$10.55M–
Q2 FY2022Jun 30, 2022-$10.04M–
Q1 FY2022Mar 31, 2022-$13.58M–

More Structure Therapeutics figures

See a number that looks wrong?